No Data
No Data
M&A Is Back. 4 Stocks That Could Be Targets
By Jacob Sonenshine Mergers are back -- and that means opportunity for small-cap investors. Small-caps don't have a lot going for them. The Russell 2000 index has gained 0.2% this year, lagging the
Check Out What Whales Are Doing With AMGN
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 67 trades.If we consider the specifics of each trade,
Here Is What to Know Beyond Why Amgen Inc. (AMGN) Is a Trending Stock
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $332
RBC Capital analyst Gregory Renza maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $328 to $332.According to TipRanks data, the analyst has a success rate of 45.4% and a
Amgen's Dezmaab injection has been approved for a new indication in China.
DiShuSingle Antibody Injection has been approved for three indications in China.
No Data